[{"address1": "350 Hills Street", "address2": "Suite 106", "city": "Richland", "state": "WA", "zip": "99354", "country": "United States", "phone": "509 375 1202", "fax": "509 267 3670", "website": "https://www.perspectivetherapeutics.com", "industry": "Medical Devices", "industryKey": "medical-devices", "industryDisp": "Medical Devices", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Perspective Therapeutics, Inc. has clinical collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety and tolerability of alpha-particle therapy [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.", "fullTimeEmployees": 91, "companyOfficers": [{"maxAge": 1, "name": "Mr. Johan M. Spoor", "age": 51, "title": "CEO & Director", "yearBorn": 1972, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan R. Hunt", "age": 56, "title": "CFO & Co-Principal Financial Officer", "yearBorn": 1967, "fiscalYear": 2009, "totalPay": 144119, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shane  Cobb", "title": "Executive Vice President of Operations", "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark J. Austin CPA", "age": 36, "title": "VP of Finance, Controller, Co-Principal Financial, Principal Accounting Officer & Secretary", "yearBorn": 1987, "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael K. Schultz Ph.D.", "title": "Chief Science Officer", "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Bright", "title": "Executive Vice President of Brachytherapy", "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Markus  Puhlmann M.B.A., M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Amos  Hedt BA, PGradDip", "title": "Chief Business Strategy Officer", "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frances L. Johnson M.D.", "title": "Chief Innovation Officer", "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Hauser Ph.D.", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2009, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1262217600, "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 1.45, "dayLow": 1.41, "dayHigh": 1.6, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 1.45, "regularMarketDayLow": 1.41, "regularMarketDayHigh": 1.6, "beta": 1.534, "forwardPE": -13.454546, "volume": 4531979, "regularMarketVolume": 4531979, "averageVolume": 3099919, "averageVolume10days": 3627370, "averageDailyVolume10Day": 3627370, "bid": 1.46, "ask": 1.52, "bidSize": 3100, "askSize": 1400, "marketCap": 868465536, "fiftyTwoWeekLow": 0.21, "fiftyTwoWeekHigh": 1.6, "priceToSalesTrailing12Months": 137.67685, "fiftyDayAverage": 1.0146, "twoHundredDayAverage": 0.55825, "currency": "USD", "enterpriseValue": 322008224, "floatShares": 187906833, "sharesOutstanding": 586801024, "sharesShort": 1880666, "sharesShortPriorMonth": 3005886, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.0032, "heldPercentInsiders": 0.30882, "heldPercentInstitutions": 0.07079, "shortRatio": 0.64, "shortPercentOfFloat": 0.0032, "impliedSharesOutstanding": 596265984, "bookValue": 0.352, "priceToBook": 4.2045455, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -29010000, "trailingEps": -0.06, "forwardEps": -0.11, "enterpriseToRevenue": 51.048, "enterpriseToEbitda": -8.097, "52WeekChange": 1.1449275, "SandP52WeekChange": 0.26653707, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "CATX", "underlyingSymbol": "CATX", "shortName": "Perspective Therapeutics, Inc.", "longName": "Perspective Therapeutics, Inc.", "firstTradeDateEpochUtc": 1131633000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a1707dc4-5cfd-3847-8a2b-6645f98c24d4", "messageBoardId": "finmb_9934314", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.48, "targetHighPrice": 1.5, "targetLowPrice": 1.2, "targetMeanPrice": 1.4, "targetMedianPrice": 1.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 17983000, "totalCashPerShare": 0.064, "ebitda": -39769000, "totalDebt": 3306000, "quickRatio": 2.429, "currentRatio": 2.673, "totalRevenue": 6308000, "debtToEquity": 3.347, "revenuePerShare": 0.027, "operatingCashflow": -33999000, "revenueGrowth": 0.273, "grossMargins": 0.051680002, "operatingMargins": -4.82105, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-07"}]